A phase III clinical trial demonstrated Jakavi (ruxolitinib) significantly improved hematocrit control without the need for phlebotomy and reduced spleen size in patients with polycythemia vera who had an inadequate response to or unacceptable side effects from hydroxyurea, as defined according to the modified European LeukemiaNet criteria.
On Nov. 5, as the American people expressed their will, electing Donald Trump to a second term, I started to wonder what my friends in oncology were thinking.
